Pruritus - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 123 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Pruritus - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Pruritus - Pipeline Review, H2 2016', provides an overview of the Pruritus pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Pruritus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pruritus and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pruritus
- The report reviews pipeline therapeutics for Pruritus by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Pruritus therapeutics and enlists all their major and minor projects
- The report assesses Pruritus therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Pruritus

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Pruritus
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Pruritus pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table Of Content

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Pruritus Overview 10
Therapeutics Development 11
Pipeline Products for Pruritus - Overview 11
Pipeline Products for Pruritus - Comparative Analysis 12
Pruritus - Therapeutics under Development by Companies 13
Pruritus - Therapeutics under Investigation by Universities/Institutes 15
Pruritus - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Pruritus - Products under Development by Companies 19
Pruritus - Products under Investigation by Universities/Institutes 21
Pruritus - Companies Involved in Therapeutics Development 22
Albireo AB 22
Alveonix AG 23
Amorepacific Corporation 24
Asana BioSciences, LLC 25
Cara Therapeutics, Inc. 26
Chugai Pharmaceutical Co., Ltd. 27
Creabilis SA 28
ELORAC, Inc. 29
Faes Farma, S.A. 30
GlaxoSmithKline Plc 31
Hydra Biosciences, Inc. 32
LEO Pharma A/S 33
Merck & Co., Inc. 34
NeRRe Therapeutics Ltd 35
Nippon Shinyaku Co., Ltd. 36
Patara Pharma, Inc. 37
Phosphagenics Limited 38
RDD Pharma Ltd. 39
Sanwa Kagaku Kenkyusho Co., Ltd. 40
Shionogi & Co., Ltd. 41
Sumitomo Dainippon Pharma Co., Ltd. 42
Teikoku Pharma USA, Inc. 43
Tioga Pharmaceuticals, Inc. 44
Trevi Therapeutics, Inc. 45
Vanda Pharmaceuticals Inc. 46
Pruritus - Therapeutics Assessment 47
Assessment by Monotherapy Products 47
Assessment by Target 48
Assessment by Mechanism of Action 50
Assessment by Route of Administration 53
Assessment by Molecule Type 55
Drug Profiles 57
A-4250 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
aprepitant - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
asimadoline - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
ASN-008 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
Ax-10 - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
Ax-8 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
bilastine - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
cromolyn sodium - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
CT-327 - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
CT-340 - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
desloratadine - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
difelikefalin - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
GSK-2330672 - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
lidocaine hydrochloride - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
nalbuphine hydrochloride ER - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
naloxone hydrochloride - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
nemolizumab - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
NS-141 - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
orvepitant maleate - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
PAC-14028 - Drug Profile 92
Product Description 92
Mechanism Of Action 92
R&D Progress 92
Peptides to Target TRPV1 for Pain and Itch - Drug Profile 94
Product Description 94
Mechanism Of Action 94
R&D Progress 94
RDD-1609 - Drug Profile 95
Product Description 95
Mechanism Of Action 95
R&D Progress 95
serlopitant - Drug Profile 96
Product Description 96
Mechanism Of Action 96
R&D Progress 96
SK-1405 - Drug Profile 98
Product Description 98
Mechanism Of Action 98
R&D Progress 98
Small Molecule to Agonize CB2 for Pruritus - Drug Profile 99
Product Description 99
Mechanism Of Action 99
R&D Progress 99
Small Molecule to Inhibit Substance P for Pruritus - Drug Profile 100
Product Description 100
Mechanism Of Action 100
R&D Progress 100
Small Molecules to Antagonize Mas-Related G-Protein Coupled Receptor for Pruritus - Drug Profile 101
Product Description 101
Mechanism Of Action 101
R&D Progress 101
Small Molecules to Antagonize TRPV3 for Pruritus and Psoriasis - Drug Profile 102
Product Description 102
Mechanism Of Action 102
R&D Progress 102
Small Molecules to Block NaV1.7 Channel for Pain, Ocular Pain and Pruritus - Drug Profile 103
Product Description 103
Mechanism Of Action 103
R&D Progress 103
TPU-010 - Drug Profile 104
Product Description 104
Mechanism Of Action 104
R&D Progress 104
tradipitant - Drug Profile 105
Product Description 105
Mechanism Of Action 105
R&D Progress 105
Pruritus - Dormant Projects 107
Pruritus - Discontinued Products 109
Pruritus - Product Development Milestones 110
Featured News & Press Releases 110
Jun 09, 2016: Cara Therapeutics to Present Preclinical Data at June Medical Meetings 110
Feb 18, 2016: Cara Therapeutics to Sponsor Symposium and Present Poster at the American Academy of Pain Medicine 32nd Annual Meeting 110
Oct 26, 2015: Cara Therapeutics to Present at 2nd Human Abuse Liability & Abuse-Deterrent Formulations Conference 111
Sep 09, 2015: Cara Therapeutics Initiates Phase 3 Program for I.V. CR845 in Acute Postoperative Pain 112
Jun 11, 2015: Tioga Pharmaceuticals Announces Initiation of Phase 2 Clinical Study of Asimadoline in Patients with Pruritus Associated with Atopic Dermatitis 112
May 12, 2015: Cara Therapeutics provides update on its Phase 3 Program for I.V. CR845 113
Apr 15, 2015: Cara Therapeutics to Present at 3rd Conference on the Therapeutic Potential of Kappa Opioids 114
Mar 19, 2015: Creabilis' CT327 Phase 2b Data Published in Acta Dermato-Venereologica, Strengthens Scientific Advisory Board 114
Mar 04, 2015: Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 115
Jan 12, 2015: Creabilis Receives Positive Feedback on CT327 from US FDA, Providing Clear Path to Registration 117
Dec 17, 2014: Cara Therapeutics Reports Positive Top-Line Data From Phase 1b Trial of I.V. CR845 in Dialysis Patients 117
Dec 17, 2014: Velocity Pharmaceutical Development and Tigercat Pharma Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 118
Aug 06, 2014: Cara Therapeutics Initiates Proof-of-Concept Phase II Trial of I.V. CR845 in Uremic Pruritus 119
Mar 21, 2014: Creabilis to Present CT327 Phase 2b Data at American Academy of Dermatology Annual Meeting 119
Jan 23, 2014: Start of Phase II study of neurokinin-1 receptor antagonist orvepitant for intense pruritus induced by epidermal growth factor receptor inhibitors 120
Appendix 122
Methodology 122
Coverage 122
Secondary Research 122
Primary Research 122
Expert Panel Validation 122
Contact Us 122
Disclaimer 123

List Of Tables

Number of Products under Development for Pruritus, H2 2016 11
Number of Products under Development for Pruritus - Comparative Analysis, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Number of Products under Development by Companies, H2 2016 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Comparative Analysis by Late Stage Development, H2 2016 16
Comparative Analysis by Clinical Stage Development, H2 2016 17
Comparative Analysis by Early Stage Development, H2 2016 18
Products under Development by Companies, H2 2016 19
Products under Development by Companies, H2 2016 (Contd..1) 20
Products under Investigation by Universities/Institutes, H2 2016 21
Pruritus - Pipeline by Albireo AB, H2 2016 22
Pruritus - Pipeline by Alveonix AG, H2 2016 23
Pruritus - Pipeline by Amorepacific Corporation, H2 2016 24
Pruritus - Pipeline by Asana BioSciences, LLC, H2 2016 25
Pruritus - Pipeline by Cara Therapeutics, Inc., H2 2016 26
Pruritus - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2016 27
Pruritus - Pipeline by Creabilis SA, H2 2016 28
Pruritus - Pipeline by ELORAC, Inc., H2 2016 29
Pruritus - Pipeline by Faes Farma, S.A., H2 2016 30
Pruritus - Pipeline by GlaxoSmithKline Plc, H2 2016 31
Pruritus - Pipeline by Hydra Biosciences, Inc., H2 2016 32
Pruritus - Pipeline by LEO Pharma A/S, H2 2016 33
Pruritus - Pipeline by Merck & Co., Inc., H2 2016 34
Pruritus - Pipeline by NeRRe Therapeutics Ltd, H2 2016 35
Pruritus - Pipeline by Nippon Shinyaku Co., Ltd., H2 2016 36
Pruritus - Pipeline by Patara Pharma, Inc., H2 2016 37
Pruritus - Pipeline by Phosphagenics Limited, H2 2016 38
Pruritus - Pipeline by RDD Pharma Ltd., H2 2016 39
Pruritus - Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H2 2016 40
Pruritus - Pipeline by Shionogi & Co., Ltd., H2 2016 41
Pruritus - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016 42
Pruritus - Pipeline by Teikoku Pharma USA, Inc., H2 2016 43
Pruritus - Pipeline by Tioga Pharmaceuticals, Inc., H2 2016 44
Pruritus - Pipeline by Trevi Therapeutics, Inc., H2 2016 45
Pruritus - Pipeline by Vanda Pharmaceuticals Inc., H2 2016 46
Assessment by Monotherapy Products, H2 2016 47
Number of Products by Stage and Target, H2 2016 49
Number of Products by Stage and Mechanism of Action, H2 2016 51
Number of Products by Stage and Route of Administration, H2 2016 54
Number of Products by Stage and Molecule Type, H2 2016 56
Pruritus - Dormant Projects, H2 2016 107
Pruritus - Dormant Projects (Contd..1), H2 2016 108
Pruritus - Discontinued Products, H2 2016 109